Literature DB >> 3523096

Selective dopamine D2 receptor reduction enhances a D1-mediated oral dyskinesia in rats.

H Rosengarten, J W Schweitzer, A J Friedhoff.   

Abstract

We have previously shown, through the use of selective D1 and D2 dopamine receptor interactive drugs, that repetitive jaw movements in rats can be produced by activation of the D1 system or blockade of the D2 system. In the present study we have shown that genetic or developmental factors resulting in a lesser number of D2--relative to D1--receptors is associated with repetitive jaw movements. We have found in two strains of rats with different striatal D2 to D1 ratios, the strain with fewer D2 sites had more jaw movements. We also found that experimental reduction of D2 receptors via prenatal intervention resulted in an increase in spontaneous jaw movements, as did aging, which is accompanied by a decrease in the number of D2 receptors. The findings of these studies carried out in rats, parallel, in a number of ways, findings in human oral dyskinesia associated with either aging or neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523096     DOI: 10.1016/0024-3205(86)90434-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  26 in total

1.  Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors.

Authors:  D Eilam; H Talangbayan; G Canaran; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.

Authors:  S A Parashos; C Marin; P Barone; V Kapitzoglou-Logothetis; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

4.  Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.

Authors:  A M Deveney; J L Waddington
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.

Authors:  A G Molloy; J L Waddington
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

6.  Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

10.  Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

Authors:  A M Deveney; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.